Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells
Lanfang Qin(Pancreatic Cancer Action Network), Rachel Schiff(Baylor College of Medicine), Huizhong Hu(Baylor College of Medicine), Carolina Gutiérrez(Baylor College of Medicine), Gary C. Chamness(Baylor College of Medicine), Sabrina Herrera(Mayo Clinic), C. Kent Osborne(Baylor College of Medicine), Joe W. Gray(Norwegian Cancer Society), Sung Yun Jung(Baylor College of Medicine), Chad J. Creighton(Baylor College of Medicine), Mario Giuliano(Regione Campania), Xiaoyong Fu(King University), Chad A. Shaw(Baylor College of Medicine), Sarmistha Nanda(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), Laura M. Heiser(Oregon Health & Science University), Xiaowei Xu(Guangdong Provincial People's Hospital), M. Hahn(Baylor College of Medicine), Martin J. Shea(Baylor College of Medicine), Dean P. Edwards(Baylor College of Medicine), Nicholas Wang(Oregon Health & Science University)
Cited by 1
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k